Introduction
Cytochrome P450 (CYP) 3A enzymes are expressed in the liver, kidney and intestine in humans and are responsible for the metabolism of >50% of clinically used drugs (Shimada et al., 1994; Guengerich, 1999; Guengerich, 2008) . Twenty genetic variants that lead to amino acid substitution have been identified in the CYP3A4 gene (http://www.cypalleles.ki.se/cyp3a4.htm).
In our previous study, we compared the enzymatic activities of major CYP3A4 variants from allele with relatively higher allelic frequency, such as CYP3A4*1 (wild type),*2 (2.7% in Caucasian) ( Sata et al., 2000) , *7 (1.4 -3% in Caucasian) (Eiselt et al ., 2001; Lamba et al., 2002) , *16
(1.4-5% in Japanese) (Lamba et al., 2002; Fukushima-Uesaka et al.,2004) , and *18 (1.3-2.8% in Japanese) (Fukushima-Uesaka et al.,2004) by using Escherichia coli expression systems (Miyazaki et al., 2008) . CYP3A4.2 and CYP3A4.16 exhibited lower catalytic activity for 6-β hydroxylation of testosterone (TST), a probe substrate of CYP3A4, than CYP3A4.1 (wild type), while CYP3A4.18 had a higher activity and CYP3A4.7 had comparable activity. Other researchers have also reported similar results; the TST activity was lower in CYP3A4.2, .7, and .16 variants than CYP3A4.1 (wild type) (Sata et al., 2000; Eiselt et al., 2001; Lamba et al., 2002; Murayama et al., 2002; Fukushima-Uesaka et al.,2004) and higher with CYP3A4.18 (Kang et al., 2009) . Kang et al. (2009) have recently reported the in vivo influence of CYP3A4*18, i.e., subjects bearing the *18 allele
show low bone mineral density ostensibly because of the enhanced turnover of both TST and estrogen. Taken together, genetic variation of CYP3A4 is quite likely to be a key factor in interindividual differences in responses to CYP3A4 substrates (Kang et al., 2009 ).
On the other hand, inhibition of CYP3A4 is a major cause of drug-drug interactions (DDI) because CYP3A4 is responsible for the metabolism of many drugs that are widely used in the clinical settings (Zhou et al., 2007) . Therefore, genetic variations of CYP3A4 that result in altered inhibitory kinetics might contribute to interindividual differences in the extent of CYP3A4-mediated DDI. However, the difference in the inhibition kinetics of CYP3A4 inhibitors between CYP3A4 genetic variants remains to be characterized. Moreover, no researchers have reported the clinical effect of genetic variation, i.e., CYP3A4*2, *7, *16 and *18, on the extent of drug-drug interaction.
Characterization of the nature of binding of substrate and inhibitor to CYP3A4 may also aid in understanding differences in the inhibitory kinetics among variants. After the crystal structure of CYP3A4 was determined (Williams et al., 2004; Yano et al., 2004) , several docking simulations have been carried out to identify the amino acid residues responsible for ligand binding (Kriegl et al., 2005; Park et al., 2005) and to reveal and predict their binding nature (Unwalla et al., 2010; Teixeira et al., 2010) .
The aims of this study were to characterize the inhibition kinetics of two typical CYP3A4
inhibitors with distinctive structures, itraconazole (ITCZ) and cimetidine (CMD), on the TST -hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a] phenanthren-3-one] was purchased from Nacalai Tesque (Kyoto, Japan).
6β-hydroxytestosterone (6β-OHT) and hydrocortisone were purchased from SPIbio bertin Pharma （ L293P） were prepared as described previously (Miyazaki et al., 2008) . All other chemicals and reagents were analytical or HPLC grade and obtained from commercial sources.
Inhibition of enzymatic activities of CYP3A4 variants by ITCZ and CMD An aliquot of 450 µl of 200 mM potassium phosphate buffer (pH 7.4) containing substrate (TST),
inhibitor (ITCZ or CMD), 0.5 mM EDTA, and CYP3A4 membrane fraction (0.5 nmol P450/ml) was pre-incubated at 37 ºC for 10 min and reactions were initiated with 50 µl of an NADPH-generating system (50 mM glucose 6-phosphate, 5 mM NADP + , 1 unit/ml glucose 6-phosphate dehydrogenase, and 30 mM MgCl 2 ) to start reaction. The reaction mixtures (total of 500 µl) were incubated for 20 min and the reactions were terminated by adding 450 µl of ice-cold acetonitrile, followed by spiking with 50 µl of 0.5 mM hydrocortisone in methanol (internal standard). After centrifugation at 1200 × g for 20 min at 4 ºC, 6β-OHT (in the supernatant) was determined by the HPLC-UV method described below. TST and ITCZ were dissolved in ethanol and methanol, with the final concentrations of solvent in reaction mixture of
respectively, which have been shown not to affect CYP3A4 activity (Chauret et al., 1998; Busby et al., 1999; Easterbrook et al., 2001) . The enzymatic activity of CYP3A4 was evaluated by determining the production rate of 6β-OHT from TST.
Analysis of 6β-OHT using HPLC-UV systems
Concentrations of 6 β-OHT were measured by an HPLC-UV method reported previously (Miyazaki et al., 2008) . Briefly, the HPLC system consisted of a pump (LC-10AD, Shimadzu, Kyoto, Japan), a
UV detector (SPD-10AV spectrophotometer, Shimadzu), and an octadecylsilane column (Cosmosil, 5C18-AR-2, 4.6 × 150 mm, Nacalai Tesque, Kyoto, Japan). The mobile phase consisted of methanol and water (58:42, v/v), pumped at a rate of 1.0 ml/min. The absorbance of 6β -OHT was measured at 254 nm, and the detection limit was 0.3 µM.
Analysis of metabolism and inhibition kinetics
The reaction rate (v) in the presence of a competitive inhibitor, such as ITCZ or CMD, is described by following Eq 1.
Eq 1 can be rearranged to give Eq 1'.
Eq 1' was simultaneously fit to the observed reaction rate at varying concentrations of substrate ( 
Docking simulations of testosterone and inhibitors to CYP3A4 variants
Molecular docking studies were performed on two-CYP3A4 specific inhibitors with CYP3A4
variants, according to our previous reported method (Okada et al., 2009; Shimada et al., 2010 
Results
Comparison of inhibition kinetics of CYP3A4 inhibition for CYP3A4 variants Both ITCZ and CMD inhibited the TST 6β-hydroxylation activity of CYP3A4 variants in a concentration-dependent manner (Fig. 1) . The K i value of ITCZ for CYP3A4.7 was 179 µM and significantly (2.4-fold) higher than that for CYP3A4.1 (76 µM), while that of CMD was 230 µM and significantly (1.6-fold) lower than that for CYP3A4.1 (370 µM) ( CYP3A4.7, the position of ITCZ is far from heme ring and its orientation is also altered. Therefore, the access of ITCZ to heme region, the reaction center for TST hydroxylation, of CYP3A4.7 was impaired in the presence of TST.
For CMD, the most stable energy states in the position of TST and CMD are shown in Figs. 2C and 2D. In CYP3A4.1, CMD was shown to dock vertically with its imidazole ring in interacting with the heme ring. However, in CYP3A4.16, CMD is docked into farther position with opposite orientation so that the access of the imidazole ring to the heme region is impaired in comparison with that in CYP3A4.1. These results are also consistent with the kinetic observations in our enzymatic study (vide supra).
This article has not been copyedited and formatted. The final version may differ from this version. )) The absolute K m and V max values in the present study were not identical to those in our previous report (Miyazaki et al., 2008) . Although the cause of this discrepancy remains uncertain, minor modification of the experimental condition, such as the composition of reaction buffer to solubilize both substrate and inhibitor in our present study, may have affected the absolute value of V max /K m . The K i value of ITCZ for TST 6β-hydroxylation in recombinant CYP3A4.1 in this study was 76 nM ( Nonspecific binding of a substrate or inhibitor to the in vitro microsomal preparation may lead to underestimation of K m or K i for an enzyme. Correction of a K i value for an inhibitor requires consideration of the unbound fraction (f u,mic ) in the microsomal preparation (Austin et al., 2002; Austin et al., 2005) . ITCZ, used in this study as a typical inhibitor, is high lipophilic and its nonspecific binding to membrane fraction is 62-91% (Isoherranen et al., 2004) in Supersomes® and 80-88% (Isoherranen et al., 2004) and 95% (Ishigam et al., 2001) in human liver microsomes.
However, the aim of present study was to investigate the relative influence of genetic variation but not to determine the absolute K i values, so accordingly we did not measure f u,mic .
Perhaps the most plausible explanation for the differences among CYP3A4 variants is conformational changes caused by amino acid substitution that may lead altered accessibility of substrate and inhibitors to the heme iron of CYP3A4. We have previously carried out docking simulation studies for substrates and inhibitors of CYP proteins, and many of the results are consistent with the enzymatic characteristics observed in the in vitro studies (Okada et al., 2009) .
In this study, we constructed a model to simulate the CYP3A4 variants with amino acid This article has not been copyedited and formatted. The final version may differ from this version. substitutions using a docking simulation program, MOE, and carried out simulation for the binding of substrates and inhibitors. As a result, CYP3A4.7 and CYP3A4.16 were shown to be structurally less suitable for access of ITCZ and CMD to the heme iron, respectively. These results are consistent with experimental observations of increased K i values. It is likely that distinctive changes in the accessibility of inhibitors to the heme iron in each variant result in the distinctive changes in the affinity of each inhibitor. Apart from the accessibility, differences in the formation of coordinate bonds between CYP3A4 and inhibitors may be also responsible for differences in the influence of genetic variation among the inhibitors. With regard to the binding of the inhibitor metyrapone to CYP3A4, it has been shown that lone electron pair of the nitrogen atom of the pyrimidine ring forms a coordinate bond with the heme iron in CYP3A4 (Park et al., 2005) . Both ITCZ and CMD have a negative charge moiety (imidazole and thiazole, respectively) that can form a coordinate bond with the CYP3A4 iron, and the differences in hydrogen bonding strength may affect the affinity of inhibitors to CYP3A4.
Similar observations regarding differences in potency of inhibitors among genetic variants have been reported in CYP2C9. Kumar et al (Kumar et al., 2006) the AUC of a substrate is increased 5-fold by the inhibitor in a CYP3A4.1 homozygote (AUC ratio = 5.0). With the equivalent concentration of inhibitor, the AUC ratio by ITCZ is predicted to be 8.4 for a CYP3A4.16 homozygote (increased DDI), whereas it is predicted to be only 2.7 in a CYP3A4.7 homozygote. For CMD (with the same assumption that AUC in CYP3A4.1 is increased 5-fold by CMD), the AUC ratio is predicted to be 7.3 for CYP3A4.7, 2.2 for CYP3A4.16 and 12 for CYP3A4.18, suggesting that genetic variation leads to interindividual variations in DDIs.
In conclusion, the potencies of typical inhibitors differed among wild type CYP3A4 and 
